Abstract Objectives We sought to identify factors associated with prognosis and bleeding in patients with melanoma brain metastases(BM).Objectives were median overall survival (mOS months) and bleeding incidence. Methods We conducted a retrospective analysis of patients receiving SRS at our center 11/1511/23.Analysis was performed on Prism 10.1.1.Extraction from electronic medical records was undertaken by authors, with local RULN(HR 4.40, P.0001).This was also true on multivariable analysis including KPS, BM number and BM size(HR 3.75 95%CI 1.94-7.30, p = 0.0001).For patients with KPS ≥90 mOS was 35.0 m vs 7.7 m for KPS ≤80(HR 2.55, P.0004).This was significant using the multivariable analysis described above(HR 2.12 95%CI 1.123-3.948, p = 0.0181). Conclusions Despite theoretically high risk of bleeding after SRS in MM BM, incidence of bleeding in our cohort was low.mOS was comparable to historical controls of 16-23 months. Advances in knowledge We novelly performed univariate and multivariate analysis demonstrating poor survival outcomes in patients with high LDH, poor performance status and larger brain metastases (both by BM size and number).
McMahon et al. (Sun,) studied this question.